57 results about "Pericyte" patented technology

The invention discloses a preparation method of a cochlear organ chip integrated with a blood labyrinth barrier, and belongs to the field of biomedical engineering. The preparation method of the simulated blood labyrinth barrier comprises the following steps: constructing an endothelial cell culture cavity and a pericyte culture cavity, and separating the endothelial cell culture cavity and the pericyte culture cavity through a simulated basement membrane; and respectively inoculating percutaneous cells and endothelial cells into a percutaneous cell culture cavity and an endothelial cell culture cavity, and culturing to obtain the simulated blood lost barrier. The chip can effectively simulate the structure and the function of the BLB, and the barrier integrity of the BLB is evaluated through TEER (trans-epithelial electrical resistance) measurement and an apparent permeability coefficient. The invention also relates to application of the chip in NIHL drug screening, in particular to drug evaluation for oxidative stress induced inner ear organ injury. Through the platform, the protection effect of the candidate drugs on the TBHP-induced oxidative stress injury of the inner ear organs can be evaluated, and a new tool and thought are provided for developing novel NIHL treatment drugs.

The invention discloses a medicine composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) through a chemical small molecule combination, and the medicine composition is used for treating sepsis. According to the invention, a chemical reprogramming strategy without genetic modification is adopted, an endogenous signal channel is activated through a time sequence, and fibroblasts from somatic cells are efficiently converted into PCLCs with high expression of genes such as EMILIN3, LAMC3, GDF10, AHR, CD109, AHR, NQO1, QPRT and the like. When applied to treatment of sepsis, the medicine composition can improve pathological symptoms and reduce death rate by synergistically exerting anti-inflammatory, anti-oxidation, immune regulation and tissue barrier protection effects. The invention provides a novel safe treatment strategy based on non-genetically modified cells for sepsis.

The invention relates to the technical field of biological medicines, and discloses application of methionine adenosine transferase 2A and related substances thereof in preparation of wound repair products. According to the application disclosed by the invention, a metabolic regulation network in a diabetic wound surface is researched, so that MAT2A expression down-regulated in pericytes is found to be remarkably and negatively correlated with M1 type macrophage infiltration, and the situation that the wound healing is delayed, the wound surface blood perfusion is reduced and the inflammation macrophage infiltration is increased due to MAT2A specific deletion of the pericytes in the wound is observed; and after saMAT2A-loaded pericellular membrane coated lipid nanoparticles (PMCNPs) are further adopted for treatment, the regeneration process of the wound surface can be remarkably enhanced, continuous inflammatory macrophage infiltration in the diabetic wound surface is relieved, microcirculation recovery is promoted, the safety is high, and good application prospects are achieved in the aspect of promoting wound surface repair.

The present invention relates to an antibody trans-binding to a TEK receptor tyrosine kinase 2 (Tie2) of different cells, and a use thereof, and, more specifically, to: an antibody and use thereof, the antibody trans-binding to Tie2 of different cells so as to improve integrity between endothelial cells, perivascular cells, or endothelial cells and perivascular cells, thereby exhibiting preventive, ameliorative, or therapeutic effects on diseases associated with angiogenesis and increased vascular permeability, or diseases associated with decreased normal angiogenesis. The antibody trans-binding to an extracellular domain of the Tie2 protein, of the present invention, has excellent in vivo vascular protective activity and angiogenesis inhibitory activity, and the cluster of the antibody exhibits the activity of promoting angiogenesis, and thus can be very effectively used in the development of therapeutic agents for preventing, alleviating, or treating diseases associated with angiogenesis, increased vascular permeability, or decreased normal angiogenesis.

The application discloses a use of a solute carrier family 25A33 gene in preparation of a medicament for treating presbycusis, and the use is achieved by enhancing SLC25A33 expression on an endolymphatic vascular stripe, by maintaining mitochondrial function stability of pericyte cells around the vascular stripe, by reducing active oxygen free radical (ROS) generation, and by blocking TGFbeta / SMAD pathway-mediated pericyte differentiation, so as to protect the integrity of the blood labyrinth barrier. Animal experiments show that overexpression of SLC25A33 can significantly reduce the hearing threshold of a presbycusis model mouse, protect the structure of the blood labyrinth barrier, and improve the expression of tight junction proteins, and the SLC25A33 gene has the potential to treat presbycusis.

The present invention relates to pharmaceutical compounds and formulations comprising said compounds, wherein said compounds have the structure according to Formula I or II. The compounds and formulations are suitable for use as medicaments for the prevention or treatment of diseases or conditions characterized by percutaneous cell dysfunction, detachment and / or loss, for medical treatment for vascular stabilization, for treatment for promoting, restoring or maintaining attachment of percutaneous cells to blood vessels, and / or for the treatment of vascular-related diseases in patients. (I) (II)

The present invention relates to a composition for preventing or treating diabetic retinopathy, comprising a peptide having an excellent effect of inhibiting the generation of neovascularization in the retina, the loss of perivascular cells, and the expansion of blood vessels. The present invention can be effectively used in the prevention or treatment of retinopathy by inhibiting increase in vascular permeability, inflammation, and the occurrence of neovascularization.

The present invention provides methods of differentiating pericytes from pluripotent stem cells comprising culturing steps in chemically defined culture medium. A population of exogenously derived pericytes from PSCs are also contemplated. Further uses of the exogenously cultured pericytes for an in vitro disease model or in vitro angiogenesis assay are contemplated, including an in vitro 3D model of vasculature.

Provided is a structure composed of a cell population comprising endothelial cells, astrocytes and pericytes, and a 3D (three dimensional) cell growth material within which the cell population is located. The structure has a TEER value of at least 450 Ω / cm2. The cells of the structure may be derived from the brain. The cells may be human cells, and in particular may be primary derived non-immortalised cells. The structure is particularly suited for use in a model of the blood brain barrier, and the invention also provides such a model. The structure is located in a container, in which it separates a first chamber located on a first side of the structure and a second chamber located on a second side of the structure. The first and second chambers respectively contain first and second liquids in contact with first and second sides of the structure. The liquids mimic the brain extracellular fluid and the blood. The blood brain barrier model provided may be used in models of brain disease, and to investigate uptake of agents into the brain or diseased brain.

A multi-chimeric cell created by ex vivo fusion of three or more hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, or satellite cells, or a combination thereof, from three or more different donors is provided, as is the use of these cells in transplant therapy and treatment of immune deficiency and genetic disorders.

The invention discloses a pericyte targeting active peptide and application thereof in preparation of antitumor drugs, and relates to the technical field of medicines. The percutaneous cell targeting active peptide is obtained by condensation of NKX2-3 fragment peptide RVLFSQAQV, FELERRFKQQ, RYLSAPEREH, LASSLKLTST, QVKIWFQNRR or YKCKRQ and N-carbobenzoxy dipeptide (Z-Gly-Pro, Z-GP), and the fragment peptide RVLFSQAQV, FELERRFKQQ, RYLSAPEREH, LASSLKLTST, QVKIWFQNRR or YKCKRQ and N-carbobenzoxy dipeptide (Z-Gly-Pro, Z-GP) are respectively Z-GP-NB1, Z-GP-NB2, Z-GP-NB3, Z-GP-NB4 The percutaneous cell targeting active peptide can effectively block the transcriptional activity of NKX2-3, recover the contractility of tumor percutaneous cells and enhance the local vascular tension of tumors, so that the tumor distal metastasis is inhibited, and the percutaneous cell targeting active peptide is expected to be applied to the treatment of patients with malignant tumors accompanied by the distal metastasis.

The invention discloses an application of a solute carrier family 25A33 gene in preparation of a medicine for treating senile deafness, which is characterized in that SLC25A33 expression on inner ear vascular lines is enhanced, the mitochondrial function stability of vascular periripple cells is maintained, the production of reactive oxygen species (ROS) is reduced, and pericyte differentiation mediated by a TGF (Transforming Growth Factor) beta / SMAD pathway is blocked, so that the senile deafness is inhibited, and the senile deafness is inhibited. Therefore, the integrity of the blood lost barrier is protected. Animal experiments show that overexpression of the SLC25A33 can significantly reduce the hearing threshold of an age-related deafness model mouse, protect the structure of a blood labyrinth barrier and improve the expression of tight junction protein, and the SLC25A33 gene has the potential of treating age-related deafness.

The present invention relates to a microfluidic device configured to study epithelial and / or endothelial barrier function in a human 3D cell microtissue model, while simultaneously allowing for the application of mechanical stimuli such as luminal flow and / or lateral flow. Embodiments include three cultures representing the maternal-fetal interface (placental barrier): human umbilical vein endothelial cells (HUVEC), human placental fibroblasts (HPF), and human placental pericytes (HPP), as well as a ductal interface composed of human primary mammary gland-derived endothelial cells, fibroblasts, and epithelial layer (MCF10). The model is expandable to include tumors (cell line-derived or patient-derived). The present invention further relates to a method for fabricating a human 3D vascular microtissue model using a microfluidic device according to the present invention, and to the use of a human 3D vascular microtissue model for, for example, studying the effects of cell barrier function (solute permeability), interstitial flow, luminal flow and / or lateral flow, and epithelial and / or endothelial barrier function (solute permeability), and extravascular matrix properties (diffusivity, stiffness, transport of molecules, antibodies and / or cells, and matrix proteins). The present invention further relates to a method for presenting a pre-eclampsia (disease) model of the placental barrier, and means for testing drug therapies.

The present invention relates to a composition for inducing differentiation of cranial neural crest stem cells into perivascular cells, a method for producing perivascular cells from cranial neural crest stem cells, and a cell therapeutic agent composition for preventing or treating brain nervous system diseases using the perivascular cells or bone diseases using the cranial neural crest stem cells. The composition and method for inducing differentiation of cranial neural crest stem cells into perivascular cells according to an aspect of the present invention enable the specific production of from cranial neural crest stem cells. In addition, the perivascular cells can be used as a cell therapeutic agent for brain nervous system diseases and using the cranial neural crest stem cells can be used as a cell therapeutic agent for bone diseases.

The application provides a specific single biomarker NADH dehydrogenase alpha subcomplex subunit 4-L2 (NDUFA4L2) for detecting pericytes. The biomarker is located in the mitochondria of pericytes. The application also provides application of NDUFA4L2 in pericyte identification. The specific single biomarker NDUFA4L2 provided by the application has a pericyte recognition accuracy of more than 90%, which is higher than the accuracy of pericyte recognition of the previously generally considered pericyte marker, and can be used as a novel single pericyte biomarker with higher specificity.

The invention provides a smoke disease model and a construction method and application thereof, and belongs to the technical field of smoke disease model construction. The method for constructing the smog disease model comprises the following steps: extracting CD34 + hematopoietic progenitor cells in peripheral blood of a smog disease patient, reprogramming to generate hiPSC, further differentiating into brain organs and vascular organs, fusing the brain organs and the vascular organs, and culturing and constructing the vascularized brain organ smog disease model. The smoke disease model constructed by adopting the construction method disclosed by the invention can simulate and reproduce phenotypes such as tiny branch increase, macrovascularization, pericytopenia, smooth muscle fibrosis deposition, abnormal angiogenesis increase and the like in clinical core pathological phenotypes of smoke disease patients, and is superior to existing animal and cell models to a certain extent.

The present disclosure is directed to methods of genetically subtyping peripheral t-cell lymphoma.

This product is an eye beauty device that stimulates the cells around the eyes with microcurrents, thereby promoting blood circulation and providing beauty benefits.

To provide STAT degraders and uses thereof.SOLUTION: The present invention provides compounds, compositions thereof, and methods of using the compositions. In some embodiments, the present invention provides a method of treating a hematologic malignancy selected from LGL leukemia (T cell and NK cell), cutaneous T cell lymphoma (CTCL), peripheral T cell lymphomas (PTCL, all subtypes including ALCL), diffuse large B cell lymphoma (DLBCL), acute myelogenous leukemia, multiple myeloma, and myelofibrosis.SELECTED DRAWING: None

The invention relates to the technical field of biological medicines, and discloses application of methionine adenosine transferase 2A and related substances thereof in preparation of anti-aging products. The invention finds that methionine adenosine transferase 2A (MAT2A) can induce mitochondrial metabolism brittleness through HMGCS1-mediated ubiquinone synthesis, so that the methionine adenosine transferase 2A (MAT2A) plays an unreported metabolic part-time role in regulating cell senescence. The specific improvement of the expression quantity of the MAT2A gene in the pericyte is beneficial for improving the cell proliferation activity, the cell mitochondrial respiration level, the cell oxygen consumption rate, the cell total ATP level and the expression level of a nuclear morphological marker LamB1, and meanwhile, the senescence cell percentage and the expression level of a senescence marker P21 are reduced; related substances for improving expression of methionine adenylyltransferase 2A can be used for preparing anti-aging drugs.

The present invention relates to a pharmaceutical compound and a formulation comprising the compound, wherein the compound is of formula I or II: The present invention relates to a pharmaceutical compound and a formulation having the structure shown in JPEG2026522984000107.jpg75161. The compound and the formulation are suitable for pharmaceutical use in the prevention or treatment of diseases or disorders characterized by pericyte dysfunction, detachment and / or loss; in therapeutic treatments for vascular stabilization; in treatments for promoting, restoring or maintaining pericyte adhesion to blood vessels; and / or in the treatment of vascular-related diseases in patients.

The invention relates to the technical field of cell therapy, and particularly discloses a repairable fibroblast preparation for treating pelvic organ prolapse. The active ingredients of the preparation are fibroblasts which highly express HAS1, POLR3G and DDR2 at the same time and do not express alpha-smooth muscle actin, and the preparation is compatible with pharmaceutic adjuvants such as normal saline, human serum albumin and dimethyl sulfoxide. The dosage form of the composition comprises an injection and a gel containing a hyaluronic acid matrix. The preparation method comprises the following steps: performing enzymolysis treatment to obtain primary cells, promoting repair phenotypic differentiation through estrogen induction, purifying target cells by adopting a fluorescence labeling flow sorting technology, and performing amplification in a serum-free culture medium to prepare a final preparation. According to the preparation, through the synergistic effect of fibroblasts and pericytes and the perivascular positioning characteristic, targeted repair of pelvic floor supporting tissue can be achieved; according to the preparation method, the cell phenotype stability and the preparation reproducibility are ensured by optimizing process parameters and quality control standards.

This invention discloses a combination of biomarkers, a kit, and their applications for detecting hypertrophic scars (HTS). The biomarker combination includes a core biomarker and / or auxiliary biomarker 1 and / or auxiliary biomarker 2; the core biomarker is ABCC9 and CSPG4, auxiliary biomarker 1 is RGS5 and ACTA2, and auxiliary biomarker 2 is PDGFRB and TRPC6. This invention also provides a kit containing the above biomarker combination detection reagents and a drug screening method. This invention reveals for the first time that pathological pericytes are the core fibrotic cells in HTS, breaking through the traditional understanding that fibroblasts are the dominant cells. By targeting and inhibiting the abnormal activation, proliferation, and transdifferentiation of pericytes into myofibroblasts, the generation of myofibroblasts and matrix deposition are curbed at the source, providing a new strategy for precision treatment of HTS. Compared with traditional therapies, this approach has higher specificity and can achieve early molecular warning and quantitative detection of trace tissues for HTS, effectively overcoming the lag and subjectivity of clinical morphological diagnosis.

The application provides a preparation method of pericyte-like mesenchymal stem cell exosome and application thereof in a diabetic wound surface, and relates to the fields of biotechnology, nanomedicine and regenerative medicine. The preparation method of the pericyte-like mesenchymal stem cell exosome comprises the following steps: providing pericyte-like mesenchymal stem cells (P-MSC), and inducing culture of mesenchymal stem cells (MSC) in a culture medium containing an effective concentration of a nitric oxide (NO) donor to obtain the pericyte-like mesenchymal stem cells (P-MSC). The application has the advantages of high targeting and precise repair. The P-MSC-Exo prepared by the application is rich in PDGFR-beta on the surface, so that the P-MSC-Exo can be specifically targeted and enriched at the damaged blood vessel endothelium expressing the ligand PDGF-BB, and precise delivery is achieved. The content can directly repair the mitochondrial damage of endothelial cells, and restore the cell function from the root.

The invention provides a biomarker screening method and system for radiotherapy-immunity pneumonia prediction, and relates to the technical field of biomedicine. Aiming at the problem that the timeliness and the specificity of the existing radiotherapy-immunity pneumonia diagnosis cannot be considered at the same time, the method comprises the following steps: separating peripheral blood T cells of a radiotherapy-immunity pneumonia group and a control group, carrying out T cell clustering annotation in combination with single-cell secretory proteomics, an R language and an ImMen database, and screening a key T cell subset Tc17 by utilizing an Augur algorithm; the method comprises the following steps: determining pericytes as key interaction cells of Tc17 through cell interaction analysis, and screening a radiotherapy specific up-regulation gene MFAP4; and carrying out difference analysis on the Mfap4hi week cell subpopulation, and screening out a biomarker gene set containing 18 genes on the basis of an elastic network algorithm in combination with 3-fold nested cross validation. The invention provides a key basis for early prediction and accurate intervention of radiotherapy-immunity pneumonia, and has the advantages of high specificity and strong repeatability.

The invention discloses an application of a chemical small molecule composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) in preparation of a medicine for treating blood-brain barrier repair. The invention discloses a specific combined chemical small molecule and an induction scheme thereof. The specific combined chemical small molecule can be used for efficiently reprogramming fibroblasts from somatic cells into PCLCs. Furthermore, the application potential of the obtained PCLCs in blood brain barrier repair is verified, a new strategy for avoiding the ethics and safety problems of a traditional reprogramming technology is provided for obtaining pericytes, and an experimental foundation is laid for developing cell drugs for repairing blood brain barriers.

The invention belongs to the technical field of thymus immigration cell detection, and particularly relates to a thymus immigration cell marker and application thereof, the marker comprises CD38 used for representing CD4RTE and CD8RTE, the CD38 can be used as a marker for defining thymus RTE, and a system and a kit for detecting the output function of thymus by CD3 + CD4 + CD45RA + CCR7 + CD31 + CD38 + and CD3 + CD8 + CD45RA + CCR7 + CD38 + cells are provided. Compared with the prior art, the thymus output function is detected more quickly and effortlessly, human peripheral CD4RTE can be more accurately defined by detecting the expression of the T cells CD31 and CD38, human peripheral CD8RTE cells can be more accurately defined by detecting the expression of the T cells CD38, and the CD38 can be used as a new surface molecular marker of the CD8RTE. The discovery of the CD8RTE marker supplements the existing theory, and is beneficial to the evaluation of the human thymus senescence function.

The invention relates to a biomarker of periapical cells and application of the biomarker, and belongs to the technical field of biological detection. The objective of the invention is to solve the problem that a conventional periodontal cell marker has expression overlap with other interstitial cells under an anoxic condition, cannot accurately distinguish tip periodontal cell subgroups, and hinders functional research and targeted therapy development thereof. The method comprises the following steps: screening 15 specific genes (including Adamts9, Cd93, Ctla2a, Fkbp1a, Angpt2 and the like) as periapical cell biomarkers by adopting machine learning according to brain single cell sequencing data of a high-altitude hypoxia mouse; and constructing a logistic regression prediction model to realize cell identification. According to the biomarker combination and the biomarker model, the false detection rate (lt; 5%). A new molecular marker for accurately identifying periapical cells is developed through a machine learning method based on a big data set, and a brand new breakthrough is provided for developing hypoxia response type periapical cell specific markers and functional targets.

The present application relates to the technical field of cell culture, and in particular to a pericyte and endothelial cell vascular model, a construction method thereof and application. The vascular model is a three-dimensional vascular structure formed by culturing dermal microvascular pericytes and endothelial cells on a matrigel. The construction method is as follows: obtaining dermal microvascular pericytes and preparing a pericyte cell suspension; forming a matrigel layer on an ibidi angiogenesis slide; adding the pericyte suspension to the matrigel layer and placing it in a culture box for culture, and discarding the culture medium; preparing an endothelial cell suspension by preparing endothelial cells, and adding the endothelial cell suspension to the ibidi angiogenesis slide for culture to form a vascular model. The present application innovatively proposes a three-dimensional vascular model at the cellular level, which can be constructed and obtained by cell culture, and has the technical advantages of being simple and easy to obtain, low in cost, and more in line with animal experiment ethics.

The invention discloses application of TPM1 in treatment of wet age-related macular degeneration. Research finds that TPM1 promotes angiogenesis, inflammation and fibrosis in eyes. The anti-angiogenesis effect of inhibiting TPM1 is similar to that of inhibiting VEGF-A, but the effect of inhibiting TPM1 is more remarkable in the aspect of reducing inflammation and fibrosis, so that the compound can be used as a potential target for treating wAMD. In addition, single cell sequencing finds that the TPM1 has high specific expression in CNV focus peripheral cells of a wAMD patient; functional experiments prove that the TPM1 is knocked down to significantly inhibit periodontocyte proliferation and migration, which prompts that the TPM1 participates in wAMD progress by regulating periodontocyte functions and does not respond to anti-VEGF treatment.